Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

11-11-2020 | ACR 2020 | Conference coverage | Video

LILAC: BIIB059 improves active joint count in SLE

Richard Furie discusses the potential benefits of BIIB059, an antibody that blocks blood dendritic cell antigen 2, in the treatment of systemic lupus erythematosus and the science behind its phase 2 success (4:47).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

08-11-2020 | ACR 2020 | Conference coverage | News

BIIB059 improves active total joint count in systemic lupus erythematosus

09-09-2020 | Systemic lupus erythematosus | News

Preliminary results support further investigation of type I IFN inhibitor for SLE

11-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | News

TULIP-1 results fail to support phase II findings for anifrolumab in SLE

13-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | News

TULIP-2 meets primary endpoint for anifrolumab efficacy in SLE
Image Credits